Opinion|Videos|November 25, 2024
Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Efficacy, safety, dosing frequency, and patient-specific factors are key in selecting NMOSD therapies.
- Eculizumab and ravulizumab may be preferred for patients with severe relapses or contraindications to B-cell depletion.
A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What factors should be considered when choosing between other available FDA-approved therapies (eculizumab, inebilizumab, satralizumab, and ravulizumab) for patients with NMOSD?
- What clinical characteristics can help guide neurologists in selecting eculizumab or ravulizumab versus rituximab?
- Discuss shared decision-making when managing patients with APQ4+ NMOSD.
Advertisement
Related to this article
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
2
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
3
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
4
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
5